HTML Microdata document

This HTML5 document contains 85 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n16	http://www.rxlist.com/cgi/generic3/
n29	http://linked.opendata.cz/resource/drugbank/drug/DB00515/identifier/national-drug-code-directory/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n22	http://linked.opendata.cz/resource/AHFS/
n10	http://linked.opendata.cz/resource/mesh/concept/
foaf	http://xmlns.com/foaf/0.1/
n4	http://linked.opendata.cz/resource/drugbank/company/
n24	http://linked.opendata.cz/resource/drugbank/dosage/
n19	http://linked.opendata.cz/resource/drugbank/drug/DB00515/identifier/chemspider/
n17	http://linked.opendata.cz/resource/drugbank/drug/DB00515/identifier/chebi/
n14	http://bio2rdf.org/drugbank:
n6	http://linked.opendata.cz/resource/drugbank/drug/DB00515/identifier/wikipedia/
adms	http://www.w3.org/ns/adms#
n26	http://linked.opendata.cz/resource/drugbank/drug/DB00515/identifier/pharmgkb/
n18	http://linked.opendata.cz/resource/drugbank/drug/DB00515/identifier/kegg-compound/
n25	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n27	http://linked.opendata.cz/resource/drugbank/drug/DB00515/identifier/pubchem-compound/
n11	http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9	http://linked.opendata.cz/ontology/mesh/
owl	http://www.w3.org/2002/07/owl#
n3	http://linked.opendata.cz/ontology/drugbank/
n21	http://www.drugs.com/cdi/
n12	http://linked.opendata.cz/resource/drugbank/property/
n28	http://linked.opendata.cz/resource/drugbank/drug/DB00515/identifier/kegg-drug/
n30	http://linked.opendata.cz/resource/drugbank/drug/DB00515/identifier/pubchem-substance/
xsdh	http://www.w3.org/2001/XMLSchema#
n20	http://linked.opendata.cz/resource/drugbank/drug/DB00515/identifier/drugbank/
n8	http://linked.opendata.cz/resource/atc/
n7	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00515
rdf:type: n3:Drug
n3:description: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
n3:dosage: n24:271B63E5-363D-11E5-9242-09173F13E4C5 n24:271B63E1-363D-11E5-9242-09173F13E4C5 n24:271B63E2-363D-11E5-9242-09173F13E4C5 n24:271B63E3-363D-11E5-9242-09173F13E4C5 n24:271B63E4-363D-11E5-9242-09173F13E4C5
n3:generalReferences: # FDA label
n3:group: approved
n3:halfLife: Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2. Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.
n3:indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
n3:manufacturer: n4:271B63DD-363D-11E5-9242-09173F13E4C5 n4:271B63DB-363D-11E5-9242-09173F13E4C5 n4:271B63DE-363D-11E5-9242-09173F13E4C5 n4:271B63DF-363D-11E5-9242-09173F13E4C5 n4:271B63DC-363D-11E5-9242-09173F13E4C5
owl:sameAs: n14:DB00515 n25:DB00515
dcterms:title: Cisplatin
adms:identifier: n6:Cisplatin n17:27899 n18:C06911 n19:389985 n20:DB00515 n26:PA449014 n27:441203 n28:D00275 n29:0015-3072-20 n30:46504561
n3:mechanismOfAction: Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.
n3:packager: n4:271B63D1-363D-11E5-9242-09173F13E4C5 n4:271B63D8-363D-11E5-9242-09173F13E4C5 n4:271B63D9-363D-11E5-9242-09173F13E4C5 n4:271B63D6-363D-11E5-9242-09173F13E4C5 n4:271B63D7-363D-11E5-9242-09173F13E4C5 n4:271B63D4-363D-11E5-9242-09173F13E4C5 n4:271B63D5-363D-11E5-9242-09173F13E4C5 n4:271B63D2-363D-11E5-9242-09173F13E4C5 n4:271B63D3-363D-11E5-9242-09173F13E4C5 n4:271B63DA-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination: The parent compound, cisplatin, is excreted in the urine. Although small amounts of platinum are present in the bile and large intestine after administration of cisplatin, the fecal excretion of platinum appears to be insignificant.
n3:synonym: Platinol-AQ CDDP Cis-DDP cis-diamminedichloroplatinum(II)
n3:volumeOfDistribution: Volume of distribution at steady state = 11-12 L/m^2
n7:hasAHFSCode: n22:10-00-00
n3:foodInteraction: Echinacea should be used with caution, if at all, in patients receiving therapeutic immunosuppressants. Monitor for reduced efficacy of the immunosuppressant during concomitant use.
n3:proteinBinding: Cisplatin does not undergo instantaneous and reversible binding to plasma protein that is characteristic of normal drug-protein binding. However, the platinum itself is capable of binding to plasma proteins, including albumin, transferrin, and gamma globulin. Three hours after a bolus injection and two hours after the end of a three-hour infusion, 90% of the plasma platinum is protein bound.
n3:synthesisReference: Murray A. Kaplan, Alphonse P. Granatek, "Process for the preparation of microcrystalline cisplatin." U.S. Patent US4322391, issued March 30, 1982.
n9:hasConcept: n10:M0004505
foaf:page: n16:cisplatin.htm n21:cisplatin.html
n3:IUPAC-Name: n12:271B63E7-363D-11E5-9242-09173F13E4C5
n3:InChI: n12:271B63ED-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n12:271B63EC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n12:271B63E9-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n12:271B63EA-363D-11E5-9242-09173F13E4C5
n3:SMILES: n12:271B63EB-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n12:271B63FC-363D-11E5-9242-09173F13E4C5
n3:logP: n12:271B63E6-363D-11E5-9242-09173F13E4C5 n12:271B63FE-363D-11E5-9242-09173F13E4C5
n7:hasATCCode: n8:L01XA01
n3:H-Bond-Acceptor-Count: n12:271B63F3-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n12:271B63F4-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n12:271B63EE-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n12:271B63EF-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n12:271B63F1-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n12:271B63F0-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n12:271B63F2-363D-11E5-9242-09173F13E4C5
n3:absorption: Following cisplatin doses of 20 to 120 mg/m^2, the concentrations of platinum are highest in liver, prostate, and kidney; somewhat lower in bladder, muscle, testicle, pancreas, and spleen; and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum. Platinum is present in tissues for as long as 180 days after the last administration.
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 15663-27-1
n3:category
n3:clearance: * 15-16 L/h/m^2 [total body clearance, 7-hour infusion of 100 mg/m^2] * 62 mL/min/m^2 [renal clearance, 2-hour infusion of 100 mg/m^2] * 50 mL/min/m^2 [renal clearance, 6- to 7-hour infusion of 100 mg/m^2] The renal clearance of free (ultrafilterable) platinum also exceeds the glomerular filtration rate indicating that cisplatin or other platinum-containing molecules are actively secreted by the kidneys. The renal clearance of free platinum is nonlinear and variable and is dependent on dose, urine flow rate, and individual variability in the extent of active secretion and possible tubular reabsorption.
n3:containedIn: n11:271B63E0-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n12:271B63F8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n12:271B63FA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n12:271B63FB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point: n12:271B63FD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n12:271B63F7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n12:271B63F6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n12:271B63F9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n12:271B63E8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n12:271B63F5-363D-11E5-9242-09173F13E4C5